Sec Form 4 Filing - Societe des Produits Nestle S.A. @ Aimmune Therapeutics, Inc. - 2020-10-13

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Societe des Produits Nestle S.A. 2. Issuer Name and Ticker or Trading Symbol Aimmune Therapeutics, Inc. [ AIMT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) AVENUE NESTLE 55 3. Date of Earliest Transaction (MM/DD/YY) 10/13/2020 (Street) CH-1800, VEVEY, V8 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/13/2020 P 43,435,583 A $ 34.5 43,435,583 ( 1 ) I See footnote ( 2 ) Common Stock 12,727,113 ( 1 ) D Common Stock 10/13/2020 P 10,681,704 A $ 34.5 23,408,817 ( 1 ) I See footnote ( 3 ) Series A Preferred Stock 525,634 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Societe des Produits Nestle S.A. AVENUE NESTLE 55 CH-1800, VEVEY, V8 X Signatures Societe des Produits Nestle S.A., /s/ Claudio Kuoni 10/15/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )All of the shares were cancelled on October 13, 2020 pursuant to the terms of that certain Agreement and Plan of Merger, dated as of August 29, 2020 (the "Merger Agreement"), by and among Societe des Produits Nestle S.A. ("SPN"), SPN MergerSub, Inc., a wholly owned subsidiary of SPN ("Merger Sub"), and Aimmune Therapeutics, Inc. ("Aimmune"). Following effectiveness of the merger provided for in the Merger Agreement, SPN owns 100 shares of the common stock of Aimmune, which became a wholly owned subsidiary of SPN as a result of such merger, which represents all of the outstanding shares of common stock of Aimmune. ( 2 )Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and SPN, pursuant to the Merger Agreement, for any and all outstanding shares of Aimmune common stock pursuant to that certain Offer to Purchase dated September 14, 2020. ( 3 )Shares acquired pursuant to the merger provided for in the Merger Agreement.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.